Icaritin Sensitizes Thrombin- and TxA₂-Induced Platelet Activation and Promotes Hemostasis via Enhancing PLCγ2-PKC Signaling Pathways

Abstract

Background Vascular injury results in uncontrollable hemorrhage in hemorrhagic diseases and excessive antithrombotic therapy. Safe and efficient hemostatic agents which can be orally administered are urgently needed. Platelets play indispensable roles in hemostasis, but there is no drug exerting hemostatic effects through enhancing platelet function.

Methods The regulatory effects of icaritin, a natural compound isolated from Herba Epimedii, on the dense granule release, thromboxane A₂ (TxA₂) synthesis, α-granule release, activation of integrin αIIbβ3, and aggregation of platelets induced by multiple agonists were investigated. The effects of icaritin on tail vein bleeding times of warfarin-treated mice were also evaluated. Furthermore, we investigated the underlying mechanisms by which icaritin exerted its pharmacological effects.

Results Icaritin alone did not activate platelets, but significantly potentiated the dense granule release, α-granule release, activation of integrin αIIbβ3, and aggregation of platelets induced by thrombin and U46619. Icaritin also shortened tail vein bleeding times of mice treated with warfarin. In addition, phosphorylated proteome analysis, immunoblotting analysis, and pharmacological research revealed that icaritin sensitized the activation of phospholipase Cγ2 (PLCγ2)-protein kinase C (PKC) signaling pathways, which play important roles in platelet activation.

Conclusion Icaritin can sensitize platelet activation induced by thrombin and TxA₂ through enhancing the activation of PLCγ2-PKC signaling pathways and promote hemostasis, and has potential to be developed into a novel orally deliverable therapeutic agent for hemorrhages.

Keywords

icaritin - sensitizing effects - platelet activation - hemostasis - phospholipase Cγ2 - protein kinase C

Data Availability Statement

The datasets analyzed for the current study are available from the corresponding author on request.

Authors' Contribution

Z.Z., Y.L., H.L., R.G., D.H., Z.L., M.H., C.S., J.Y., and K.Z. performed most of the experiments, and contributed to the acquisition and analysis of data. Z.Z. designed the study and drafted the manuscript. N.W. contributed to the analysis of data and revised the manuscript. P.T. and G.Z. supervised the study team and revised the manuscript.

Publication History

Received: 03 April 2023

Accepted: 13 January 2024

Accepted Manuscript online:
15 January 2024

Article published online:
09 February 2024

• References

• 1 Callaghan MU, Sidonio R, Pipe SW. Novel therapeutics for hemophilia and other bleeding disorders. Blood 2018; 132 (01) 23-30
• 2 Nogami K, Shima M. New therapies using nonfactor products for patients with hemophilia and inhibitors. Blood 2019; 133 (05) 399-406
• 3 Levy JH, Koster A, Quinones QJ, Milling TJ, Key NS. Antifibrinolytic therapy and perioperative considerations. Anesthesiology 2018; 128 (03) 657-670
• 4 Runge M, Møller CH, Steinbrüchel DA. Increased accuracy in heparin and protamine administration decreases bleeding: a pilot study. J Extra Corpor Technol 2009; 41 (01) 10-14
• 5 Connolly SJ, Crowther M, Eikelboom JW. et al; ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380 (14) 1326-1335
• 6 Pollack Jr CV, Reilly PA, van Ryn J. et al. Idarucizumab for dabigatran reversal-full cohort analysis. N Engl J Med 2017; 377 (05) 431-441
• 7 Dhakal P, Rayamajhi S, Verma V, Gundabolu K, Bhatt VR. Reversal of anticoagulation and management of bleeding in patients on anticoagulants. Clin Appl Thromb Hemost 2017; 23 (05) 410-415
• 8 Trenk D, Hille L, Leggewie S. et al. Antagonizing P2Y12 receptor inhibitors: current and future options. Thromb Haemost 2019; 119 (10) 1606-1616
• 9 Nagy Jr B, Bhavaraju K, Getz T, Bynagari YS, Kim S, Kunapuli SP. Impaired activation of platelets lacking protein kinase C-θ isoform. Blood 2009; 113 (11) 2557-2567
• 10 Murugappan S, Shankar H, Bhamidipati S, Dorsam RT, Jin J, Kunapuli SP. Molecular mechanism and functional implications of thrombin-mediated tyrosine phosphorylation of PKCdelta in platelets. Blood 2005; 106 (02) 550-557
• 11 Chen X, Zhang Y, Wang Y. et al. PDK1 regulates platelet activation and arterial thrombosis. Blood 2013; 121 (18) 3718-3726
• 12 Laurent PA, Séverin S, Hechler B, Vanhaesebroeck B, Payrastre B, Gratacap MP. Platelet PI3Kβ and GSK3 regulate thrombus stability at a high shear rate. Blood 2015; 125 (05) 881-888
• 13 Stefanini L, Roden RC, Bergmeier W. CalDAG-GEFI is at the nexus of calcium-dependent platelet activation. Blood 2009; 114 (12) 2506-2514
• 14 Beck F, Geiger J, Gambaryan S. et al. Time-resolved characterization of cAMP/PKA-dependent signaling reveals that platelet inhibition is a concerted process involving multiple signaling pathways. Blood 2014; 123 (05) e1-e10
• 15 DeHelian D, Gupta S, Wu J. et al. RGS10 and RGS18 differentially limit platelet activation, promote platelet production, and prolong platelet survival. Blood 2020; 136 (15) 1773-1782
• 16 Weng Z, Li D, Zhang L. et al. PTEN regulates collagen-induced platelet activation. Blood 2010; 116 (14) 2579-2581
• 17 Li C, Li Q, Mei Q, Lu T. Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii. Life Sci 2015; 126: 57-68
• 18 Zhou L, Poon CC, Wong KY. et al. Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling. Phytomedicine 2021; 82: 153413
• 19 Sun J, Wang D, Lin J. et al. Icariin protects mouse Leydig cell testosterone synthesis from the adverse effects of di(2-ethylhexyl) phthalate. Toxicol Appl Pharmacol 2019; 378: 114612
• 20 Bi Z, Zhang W, Yan X. Anti-inflammatory and immunoregulatory effects of icariin and icaritin. Biomed Pharmacother 2022; 151: 113180
• 21 Gao L, Zhang SQ. Antiosteoporosis effects, pharmacokinetics, and drug delivery systems of icaritin: advances and prospects. Pharmaceuticals (Basel) 2022; 15 (04) 397
• 22 Hao H, Zhang Q, Zhu H. et al. Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice. Eur J Immunol 2019; 49 (12) 2235-2244
• 23 Dongye Z, Wu X, Wen Y. et al. Icaritin and intratumoral injection of CpG treatment synergistically promote T cell infiltration and antitumor immune response in mice. Int Immunopharmacol 2022; 111: 109093
• 24 Zhu Z, Wang L, Guo R. et al. XJ-8, a natural compound isolated from Sanguis draxonis, inhibits platelet function and thrombosis by targeting MAP3K3. J Thromb Haemost 2022; 20 (03) 605-618
• 25 Kim K, Tseng A, Barazia A, Italiano JE, Cho J. DREAM plays an important role in platelet activation and thrombogenesis. Blood 2017; 129 (02) 209-225
• 26 Canobbio I, Visconte C, Momi S. et al. Platelet amyloid precursor protein is a modulator of venous thromboembolism in mice. Blood 2017; 130 (04) 527-536
• 27 Babur Ö, Melrose AR, Cunliffe JM. et al. Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs. Blood 2020; 136 (20) 2346-2358
• 28 Golebiewska EM, Poole AW. Platelet secretion: from haemostasis to wound healing and beyond. Blood Rev 2015; 29 (03) 153-162
• 29 Przyborowski K, Kurpinska A, Wojkowska D. et al. Protein disulfide isomerase-A1 regulates intraplatelet reactive oxygen species-thromboxane A₂ -dependent pathway in human platelets. J Thromb Haemost 2022; 20 (01) 157-169
• 30 Bath PM, May J, Heptinstall S. Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders. Platelets 2018; 29 (05) 425-430
• 31 Huang J, Li X, Shi X. et al. Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol 2019; 12 (01) 26
• 32 Dahri K, Loewen P. The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb Haemost 2007; 98 (05) 980-987
• 33 Rydberg DM, Linder M, Malmström RE, Andersen M. Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication. Eur J Clin Pharmacol 2020; 76 (06) 867-876
• 34 Moore SFJ, van den Bosch MT, Hunter RW, Sakamoto K, Poole AW, Hers I. Dual regulation of glycogen synthase kinase 3 (GSK3)α/β by protein kinase C (PKC)α and Akt promotes thrombin-mediated integrin αIIbβ3 activation and granule secretion in platelets. J Biol Chem 2013; 288 (06) 3918-3928
• 35 Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. Blood 2003; 102 (10) 3592-3599
• 36 Rosado JA, Sage SO. Role of the ERK pathway in the activation of store-mediated calcium entry in human platelets. J Biol Chem 2001; 276 (19) 15659-15665
• 37 Fälker K, Lange D, Presek P. ADP secretion and subsequent P2Y12 receptor signalling play a crucial role in thrombin-induced ERK2 activation in human platelets. Thromb Haemost 2004; 92 (01) 114-123
• 38 Nadal-Wollbold F, Pawlowski M, Lévy-Toledano S, Berrou E, Rosa JP, Bryckaert M. Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett 2002; 531 (03) 475-482
• 39 Tong JS, Zhang QH, Huang X. et al. Icaritin causes sustained ERK1/2 activation and induces apoptosis in human endometrial cancer cells. PLoS One 2011; 6 (03) e16781
• 40 Schubert P, Coupland D, Nombalais M, M Walsh G, Devine DV. RhoA/ROCK signaling contributes to sex differences in the activation of human platelets. Thromb Res 2016; 139: 50-55
• 41 Majewski Ł, Sobczak M, Havrylov S, Jóźwiak J, Rędowicz MJ. Dock7: a GEF for Rho-family GTPases and a novel myosin VI-binding partner in neuronal PC12 cells. Biochem Cell Biol 2012; 90 (04) 565-574
• 42 Rosa JP, Raslova H, Bryckaert M. Filamin A: key actor in platelet biology. Blood 2019; 134 (16) 1279-1288
• 43 Stefanini L, Ye F, Snider AK. et al. A talin mutant that impairs talin-integrin binding in platelets decelerates αIIbβ3 activation without pathological bleeding. Blood 2014; 123 (17) 2722-2731
• 44 Ambrosio AL, Febvre HP, Di Pietro SM. Syntaxin 12 and COMMD3 are new factors that function with VPS33B in the biogenesis of platelet α-granules. Blood 2022; 139 (06) 922-935
• 45 Adam F, Kauskot A, Kurowska M. et al. Kinesin-1 is a new actor involved in platelet secretion and thrombus stability. Arterioscler Thromb Vasc Biol 2018; 38 (05) 1037-1051
• 46 Giuriato S, Payrastre B, Drayer AL. et al. Tyrosine phosphorylation and relocation of SHIP are integrin-mediated in thrombin-stimulated human blood platelets. J Biol Chem 1997; 272 (43) 26857-26863
• 47 Chari R, Kim S, Murugappan S, Sanjay A, Daniel JL, Kunapuli SP. Lyn, PKC-δ, SHIP-1 interactions regulate GPVI-mediated platelet-dense granule secretion. Blood 2009; 114 (14) 3056-3063
• 48 Xin ZC, Kim EK, Lin CS. et al. Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl 2003; 5 (01) 15-18